Clinical Trial Update: Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating inhibition of interleukin-17A for idiopathic subglottic stenosis is active but not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Subglottic Stenosis

Drugs mentioned

• IL-17A inhibitor (investigational)

Snippet

Sponsor: Yale University | Conditions: Idiopathic Subglottic Stenosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING